Exemplar加入Mayo Clinic，成立肝细胞开发公司

StephenW

Exemplar joins Mayo Clinic to launch hepatocyte development company
December 22, 2018

Exemplar Genetics in partnership with Mayo Clinic launched a new company, Cytotheryx, focused on the development of a high-quality source of human liver cells or hepatocytes for clinical research, according to a press release.

“This collaboration combines our focus on unmet needs of patients with an innovative way to drive development of new therapies,” Andrew Danielsen, vice-chair of the department of business development at Mayo Clinic, said in the release.


Exemplar Genetics will provide business and technical resources for the company, while Mayo Clinic will use any revenue it receives to support nonprofit missions in patient care, education and research.

“Throughout the United States and the world there is a desperate need for a high-quality source of [hepatocytes] for medical research and regenerative medicine applications,” John R. Swart, president of Exemplar Genetics, said in the release. “Cytotheryx has brought together the team and technology to deliver on that need.”

Cytotheryx is headquartered in Rochester, Minnesota.

Reference: www.exemplargenetics.com

StephenW

Exemplar加入Mayo Clinic，成立肝细胞开发公司
2018年12月22日

根据新闻报道，与Mayo Clinic合作的Exemplar Genetics推出了一家新公司Cytotheryx，专注于开发用于临床研究的高质量人体肝细胞或肝细胞来源。

“这项合作将我们对患者未满足需求的关注与推动新疗法开发的创新方式结合起来，”梅奥诊所业务发展部副主席Andrew Danielsen在发布会上表示。


Exemplar Genetics将为公司提供业务和技术资源，而Mayo Clinic将使用其收到的任何收入来支持患者护理，教育和研究中的非营利性任务。

“在整个美国和全世界，迫切需要用于医学研究和再生医学应用的高质量[肝细胞]来源，”Exemplar Genetics总裁John R. Swart在发布会上表示。 “Cytotheryx汇集了团队和技术，以满足这一需求。”

Cytotheryx总部位于明尼苏达州罗切斯特市。

参考：www.exemplargenetics.com

齐欢畅

StephenW 发表于 2018-12-23 20:23
Exemplar加入Mayo Clinic，成立肝细胞开发公司
2018年12月22日

能否解读一下？

StephenW

回复 齐欢畅 的帖子

Human hepatocytes are necessary for drug toxicology studies, hepatitis virus research and gene therapy testing. Further, there are opportunities to utilize cells in liver assist devices and allotransplantation to treat acute liver failure. HHCs do not grow in culture and are derived primarily from human cadaver donors, which cannot provide the quality and volume essential to meet the various demands for these cells.

“Throughout the United States and the world there is a desperate need for a high quality source of HHCs for medical research and regenerative medicine applications,” commented Dr. John R. Swart, President of Exemplar Genetics. “Cytotheryx has brought together the team and technology to deliver on that need.”

Cytotheryx, utilizing technology developed at Mayo Clinic and the expertise of Exemplar Genetics, will provide a consistent source of high quality hepatocytes to address patient needs and market shortcomings. The market opportunity for HHCs utilized for research is estimated to be $250 million annually and is in excess of $1 billion for FDA approved applications.

人肝细胞是药物毒理学研究，肝炎病毒研究和基因治疗测试所必需的。此外，有机会利用肝脏辅助装置中的细胞和同种异体移植来治疗急性肝衰竭。 HHCs不在培养物中生长并且主要来自人尸体供体，其不能提供满足这些细胞的各种需求所必需的质量和体积。

“在整个美国和全世界，迫切需要高质量的HHCs用于医学研究和再生医学应用，”Exemplar Genetics总裁John R. Swart博士评论道。 “Cytotheryx汇集了团队和技术，以满足这一需求。”

Cytotheryx利用Mayo Clinic开发的技术和Exemplar Genetics的专业知识，将提供一致的高质量肝细胞来源，以满足患者的需求和市场缺陷。用于研究的HHCs的市场机会估计每年2.5亿美元，对于FDA批准的申请超过10亿美元。

齐欢畅